Adaptive Bayesian Design for Phase I Dose-Finding Trials Using a Joint Model of Response and Toxicity

By Wang Meihua  

Journal of Biopharmaceutical Statistics, Vol. 20, Iss. 1, 2010-01 ,pp. : 125-144

Taylor & Francis Ltd

Access to resources Recommend Favorite

Fractional Dose-Finding Methods with Late-Onset Toxicity in Phase I Clinical Trials

By Yin Guosheng   Zheng Shurong   Xu Jiajing  

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 4, 2013-07 ,pp. : 856-870

Taylor & Francis Ltd

Access to resources Recommend Favorite

Recent Developments in Adaptive Designs for Phase I/II Dose-Finding Studies

By Zohar Sarah   Chevret Sylvie  

Journal of Biopharmaceutical Statistics, Vol. 17, Iss. 6, 2007-11 ,pp. : 1071-1083

Taylor & Francis Ltd

Access to resources Recommend Favorite

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)

By Keizer Ron  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1519-1530

Springer Publishing Company

Access to resources Recommend Favorite

OASIS-HT: design of a pharmacogenomic dose-finding study

By Staessen Jan A   Kuznetsova Tatiana   Acceto Rok   Bacchieri Antonella   Brand Eva   Burnier Michel   Celis Hilde   Citterio Lorena   de Leeuw Peter W   Filipovský Jan   Fournier Albert   Kawecka-Jaszcz Kalina   Manunta Paolo   Nikitin Yuri   O’Brien Eoin T   Redón Josep   Thijs Lutgarde   Ferrari Patrizia   Valentini Giovanni   Bianchi Giuseppe  

Pharmacogenomics, Vol. 6, Iss. 7, 2005-10 ,pp. : 755-775

Future Medicine

Access to resources Recommend Favorite